Trials / Not Yet Recruiting
Not Yet RecruitingNCT07354100
Lactulose to Improve Gut Health in Cancer Patients Receiving Immunotherapy
Bifidobacterium Lactulose Optimization in Oncology and Microbiome (BLOOM)
- Status
- Not Yet Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 55 (estimated)
- Sponsor
- University of Chicago · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to see if lactulose can improve the effectiveness of immunotherapy in patients with advanced cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Lactulose | Lactulose 10 g daily with standard-of-care Immune checkpoint inhibitors (ICIs). |
Timeline
- Start date
- 2026-12-15
- Primary completion
- 2029-04-13
- Completion
- 2029-04-13
- First posted
- 2026-01-21
- Last updated
- 2026-03-04
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07354100. Inclusion in this directory is not an endorsement.